{"id":"W2768649895","doi":"10.1016/s1470-2045(17)30716-7","title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":529,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Johnson and Johnson; F. Hoffmann-La Roche; Eli Lilly and Company","keywords":"Pertuzumab; Medicine; Trastuzumab; Trastuzumab emtansine; Docetaxel; Oncology; Internal medicine; Breast cancer; Carboplatin; Regimen; Neoadjuvant therapy; Metastatic breast cancer; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003502623,0.001270149,0.002595059,0.0003341782,0.0005284852,0.0009900918,0.0008576257,0.001700245,0.004709816],"category_scores_gemma":[0.002653496,0.0006493868,0.001816381,0.0003760368,0.001364842,0.001313275,0.0005947174,0.002301665,0.0006645056],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009450912,"about_ca_system_score_gemma":0.001919026,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007508401,"about_ca_topic_score_gemma":0.00226937,"domain_scores_codex":[0.9984067,0.001050591,0.00009102045,0.0001901706,0.000076545,0.0001850211],"domain_scores_gemma":[0.9982352,0.0005367089,0.0003806229,0.0001475712,0.00009002868,0.0006096984],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9860747,0.004888379,0.0003148972,0.0002564182,0.0002532214,0.00002070734,0.00005301879,0.0002452843,0.001372729,0.00006182354,0.0003446593,0.006114085],"study_design_scores_gemma":[0.9293236,0.06873528,0.0008405058,0.00002216018,0.000159355,0.00002467182,0.0000136456,0.000203319,0.0001671423,0.00009870732,0.0003998876,0.00001172367],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9868058,0.00280779,0.0005574957,0.0007015166,0.0004605748,0.006340205,0.000573152,0.00007408715,0.001679535],"genre_scores_gemma":[0.981266,0.001766638,0.002545382,0.001268484,0.0004835172,0.009640353,0.000724344,0.00002018453,0.002285256],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004709816,"threshold_uncertainty_score":0.01852387,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09179359523436297,"score_gpt":0.4422125994061898,"score_spread":0.3504190041718268,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}